Pfizer starts mid-stage trial of Omicron-targeting vaccine
Pfizer Inc and its German partner BioNTech SE said on Wednesday they had started a mid-stage study of a modified bivalent COVID-19 vaccine which also targets an Omicron variant.
The company did not disclose which subvariant of Omicron the vaccine would be targetting.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- German
- Omicron
- Pfizer Inc
- BioNTech SE
Advertisement
ALSO READ
ICC has no authority to probe Philippines, Marcos tells Germany's Scholz
Germany is only halfway through property crisis, says Commerzbank real estate boss
Soccer-Nagelsmann names six newcomers in Germany squad for France, Dutch friendlies
German government needs tighter conflict-of-interest guidelines, activists say
Euro zone bond yields edge up, Italian-German spread hits fresh 26-month low